Related Experiment Video

Updated: Jun 30, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

The MUC1 oncoprotein as a functional target: immunotoxin binding to alpha/beta junction mediates cell killing

Daniel B Rubinstein1, Maya Karmely, Edward Pichinuk

  • 1National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. danielhw@post.tau.ac.il

International Journal of Cancer
|September 30, 2008
PubMed

Insights

New antibodies targeting the MUC1 alpha/beta junction effectively kill MUC1-expressing cancer cells. This cell-bound target overcomes limitations of previous MUC1 antibodies, showing significant in vivo tumor suppression.

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • Mucin 1 (MUC1) is overexpressed in many cancers, making it a promising target for cancer therapies.
  • Current anti-MUC1 antibodies target the shed alpha chain, limiting their efficacy as they cannot reach MUC1-expressing cells.
  • The MUC1 alpha/beta junction represents a cell-bound target that may overcome these limitations.

Purpose of the Study:

  • To develop and evaluate antibodies targeting the MUC1 alpha/beta junction for cancer therapy.
  • To assess the efficacy of these antibodies in binding, internalizing, and killing MUC1-positive cancer cells.
  • To investigate the in vivo tumor-suppressive activity of antibodies targeting the MUC1 alpha/beta junction.

Main Methods:

  • Immunization with MUC1 cDNA variants to generate antibodies against the MUC1 alpha/beta junction.
  • Conjugation of Pseudomonas toxin PE38 to polyclonal anti-MUC1 alpha/beta junction antibodies.
  • Testing monoclonal antibody DMC209 binding and internalization in MUC1-expressing cells.
  • Evaluating in vivo tumor suppression in SCID mice xenotransplanted with human breast cancer cells.

Main Results:

  • Antibodies targeting the MUC1 alpha/beta junction effectively bind and kill MUC1-positive malignant cells.
  • Polyclonal antibody-toxin conjugates demonstrated potent killing of MUC1-positive cells.
  • Monoclonal antibody DMC209 showed significant in vivo tumor suppression in a human breast cancer xenograft model.
  • The MUC1 alpha/beta junction was found to be internalized into cells upon antibody binding.

Conclusions:

  • The cell-bound MUC1 alpha/beta junction is a superior target for MUC1-expressing malignancies compared to the shed alpha chain.
  • Antibodies targeting the MUC1 alpha/beta junction can be effectively used in antibody-toxin conjugates for cancer therapy.
  • Targeting the MUC1 alpha/beta junction demonstrates significant in vivo tumor suppression, offering a promising therapeutic strategy.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...